BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 2 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q3 2023. The put-call ratio across all filers is - and the average weighting 6.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,755,876 | +18.4% | 490,422 | +8.9% | 13.24% | +1.4% |
| Q2 2023 | $10,774,092 | +75.1% | 450,422 | 0.0% | 13.06% | +37.7% |
| Q1 2023 | $6,152,764 | -1.6% | 450,422 | 0.0% | 9.48% | -32.8% |
| Q4 2022 | $6,251,857 | -95.4% | 450,422 | -50.0% | 14.11% | -82.3% |
| Q3 2022 | $136,181,000 | +3.6% | 900,844 | 0.0% | 79.57% | +6.1% |
| Q2 2022 | $131,406,000 | +23.0% | 900,844 | 0.0% | 75.00% | +11.9% |
| Q1 2022 | $106,813,000 | -13.6% | 900,844 | +0.4% | 67.04% | -1.3% |
| Q4 2021 | $123,594,000 | +3.8% | 896,844 | +4.7% | 67.92% | +14.4% |
| Q3 2021 | $119,024,000 | +43.1% | 856,844 | 0.0% | 59.36% | +36.6% |
| Q2 2021 | $83,182,000 | +42.0% | 856,844 | 0.0% | 43.44% | +13.8% |
| Q1 2021 | $58,565,000 | -20.3% | 856,844 | -0.1% | 38.16% | -23.9% |
| Q4 2020 | $73,496,000 | +31.8% | 857,494 | 0.0% | 50.11% | +9.7% |
| Q3 2020 | $55,746,000 | -10.2% | 857,494 | 0.0% | 45.68% | +27.5% |
| Q2 2020 | $62,074,000 | +112.7% | 857,494 | 0.0% | 35.84% | +30.7% |
| Q1 2020 | $29,181,000 | -37.4% | 857,494 | 0.0% | 27.41% | -20.4% |
| Q4 2019 | $46,631,000 | +30.3% | 857,494 | 0.0% | 34.43% | +5.2% |
| Q3 2019 | $35,775,000 | +9.0% | 857,494 | +14.4% | 32.74% | +21.8% |
| Q2 2019 | $32,834,000 | -14.9% | 749,815 | 0.0% | 26.88% | -8.3% |
| Q1 2019 | $38,593,000 | +39.2% | 749,815 | 0.0% | 29.33% | -7.0% |
| Q4 2018 | $27,728,000 | -0.7% | 749,815 | 0.0% | 31.54% | +33.7% |
| Q3 2018 | $27,916,000 | -5.8% | 749,815 | 0.0% | 23.60% | -6.3% |
| Q2 2018 | $29,633,000 | +53.4% | 749,815 | 0.0% | 25.18% | +27.0% |
| Q1 2018 | $19,315,000 | -11.3% | 749,815 | -7.1% | 19.83% | +3.3% |
| Q4 2017 | $21,779,000 | -27.8% | 807,224 | 0.0% | 19.20% | -25.5% |
| Q3 2017 | $30,150,000 | +49.4% | 807,224 | 0.0% | 25.78% | -3.6% |
| Q2 2017 | $20,181,000 | – | 807,224 | – | 26.75% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 1,111,111 | $107,867,000 | 52.60% |
| Knoll Capital Management, LLC | 856,844 | $83,182,000 | 43.44% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,082,555 | $202,174,000 | 27.86% |
| ARS Investment Partners, LLC | 558,286 | $54,198,000 | 5.52% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $17,113,000 | 4.52% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 401,006 | $38,930,000 | 4.51% |
| Eventide Asset Management | 1,990,797 | $193,267,000 | 2.60% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 56,626 | $5,497,000 | 2.45% |
| Avidity Partners Management LP | 882,500 | $85,673,000 | 2.32% |
| Nicholas Investment Partners, LP | 363,708 | $35,309,000 | 2.22% |